NHS England has published its latest annual bowel cancer screening statistics, revealing that the programme is detecting approximately 100 cancers per week — while simultaneously flagging a persistent gap in participation among people in their 50s.
Uptake Figures for 2024–25
The data, which covers the twelve months from April 2024 to March 2025, shows that just 56.2% of 54-year-olds completed a bowel cancer screening test during that period, according to NHS England's annual bowel screening figures. That figure — representing a bare majority of those invited — is notably lower than participation rates recorded in older age groups within the same dataset.
The screening programme relies on a home-based testing kit, posted directly to eligible individuals. Completed kits are returned by post for laboratory analysis, making the process largely self-administered. Despite that convenience, the figures suggest a meaningful proportion of people in their 50s are not returning their kits.
Why the 50s Age Group Draws Attention
Bowel cancer is among the most commonly diagnosed cancers in England. Early detection is widely associated with improved clinical outcomes in oncological research, and population-level screening programmes are designed specifically to identify disease at stages when it may produce few or no symptoms.
The fact that people in their 50s are less likely to participate than other age groups is notable partly because this decade represents the earliest point at which individuals become eligible for the programme. Researchers and public health officials have long observed that first-time participants in any screening initiative tend to show lower initial uptake, a pattern sometimes attributed to unfamiliarity with the process or uncertainty about what the test involves.
Scale of Detection
The headline statistic from NHS England's release — roughly 100 bowel cancers identified through screening every week — offers a concrete illustration of the programme's reach. Across a full year, that rate would correspond to thousands of diagnoses made through a route that does not depend on a person presenting to a clinician with symptoms.
Screening-detected cancers are generally identified at an earlier stage than symptomatic cancers, a distinction that carries significance in treatment planning and prognosis, though outcomes vary considerably by individual case and tumour biology.
The Kit Itself
The NHS bowel cancer screening test currently in use is a faecal immunochemical test, commonly referred to as a FIT kit. It detects trace amounts of blood in a stool sample. A positive result does not confirm cancer — it triggers a referral for further investigation, typically a colonoscopy — but the test serves as a low-burden first filter within the screening pathway.
The home-based format was introduced partly to reduce barriers associated with clinic attendance. Postal return means the process can be completed without an appointment, and the test itself requires only a small sample collected at home.
Context Within the Broader Programme
NHS England's annual publication of bowel screening statistics allows year-on-year tracking of both uptake and detection rates. The 2024–25 figures continue a pattern in which the programme demonstrates meaningful detection volume while participation in certain demographic segments remains an area of focus for public health messaging.
The health service's current call for people in their 50s to return outstanding kits reflects an ongoing effort to close the uptake gap identified in the data. Whether targeted communications translate into measurable increases in participation will likely be assessed in subsequent annual figures.
The full dataset is available via NHS England's published announcement.